NOVO NORDISK A/S |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 910 DKK | +0.01% |
|
+3.10% | +30.35% |
| May. 14 | Health Care Up on Improved Risk Appetite -- Health Care Roundup | DJ |
| May. 14 | Eli Lilly reaches settlement with spa selling Mounjaro, Zepbound knockoffs | RE |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Hours!
Take advantage of the offer
* See conditions on site
| Sales 2024 * | 289B 41.98B | Sales 2025 * | 349B 50.64B | Capitalization | 4,054B 588B |
|---|---|---|---|---|---|
| Net income 2024 * | 104B 15.1B | Net income 2025 * | 127B 18.37B | EV / Sales 2024 * | 14.1 x |
| Net Debt 2024 * | 13.34B 1.93B | Net cash position 2025 * | 12.63B 1.83B | EV / Sales 2025 * | 11.6 x |
| P/E ratio 2024 * |
39.2
x | P/E ratio 2025 * |
32.1
x | Employees | 66,015 |
| Yield 2024 * |
1.3% | Yield 2025 * |
1.56% | Free-Float | 70.17% |
More Fundamentals
* Assessed data
More news
Latest transcript on Novo Nordisk A/S
More recommendations
More press releases
| 1 day | +0.01% | ||
| 1 week | +6.88% | ||
| Current month | +0.82% | ||
| 1 month | +3.41% | ||
| 3 months | +9.34% | ||
| 6 months | +31.22% | ||
| Current year | +30.35% |
1 week
881.60
927.00
1 month
826.70927.00
Current year
688.80932.00
1 year
504.40932.00
3 years
237.73932.00
5 years
155.08932.00
10 years
109.10932.00
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 58 | 90-12-31 | |
| Director of Finance/CFO | 53 | 98-12-31 | |
Stephen Gough
CTO | Chief Tech/Sci/R&D Officer | - | 15-09-30 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Sylvie Grégoire
BRD | Director/Board Member | 63 | 15-03-18 |
Helge Lund
CHM | Chairman | 61 | 17-03-22 |
Martin MacKay
BRD | Director/Board Member | 68 | 18-02-28 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 21.31% | 200 M€ | +17.77% | ||
| 10.45% | 5 M€ | +13.42% | ||
| 5.40% | 17 M€ | +6.46% | - | |
| 4.67% | 88 M€ | +10.37% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-14 | 910 | +0.01% | 3,118,148 |
| 24-05-13 | 909.9 | +3.02% | 4,150,455 |
| 24-05-08 | 883.2 | +0.07% | 2,737,492 |
| 24-05-07 | 882.6 | +3.66% | 9,320,634 |
Delayed Quote Nasdaq Copenhagen, May 14, 2024 at 10:59 am EDT
More quotes
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
Pharmaceuticals
Calendar
2024-08-07
- Q2 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
910
DKK
Average target price
909.2
DKK
Spread / Average Target
-0.08%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +30.35% | 586B | |
| +31.06% | 682B | |
| -3.42% | 364B | |
| +18.02% | 327B | |
| +4.27% | 285B | |
| +15.53% | 240B | |
| +10.16% | 209B | |
| -8.14% | 203B | |
| +8.12% | 165B | |
| -1.42% | 161B |
- Stock Market
- Equities
- NOVO B Stock